ZSTK — ZeroStack Corp.

Summary of Flora Growth Corp. Q1 2024 Earnings Call

1. Key Financial Results and Metrics:

• Revenue: $18 million, down from $19.3 million in Q1 2023, primarily due to the discontinuation of unprofitable product lines.
• German Operations: Revenue increased to $11.3 million from $8 million in Q1 2023.
• Operating Expenses: Reduced to $6.3 million from $7.7 million year-over-year, a decrease of 18%. Excluding noncash impairment charges, the decrease was 30%.
• Net Cash Used in Operations: Improved to $1.3 million from $4.3 million in Q1 2023, a 70% reduction.
• Net Loss: $3.4 million, slightly improved from $3.9 million in the prior year.
• Cash Position: Ended the quarter with $4.2 million in cash and $21.8 million in current assets.

2. Strategic Updates and Business Highlights:

• Germany Focus: The company is positioned to capitalize on new cannabis legislation in Germany, which allows for recreational use and simplifies access to medical cannabis.
• Acquisition: Flora acquired TruHC Pharma GmBH, enhancing its capabilities in Germany with key licenses for production and distribution.
• U.S. Expansion: The company is expanding its U.S. operations through partnerships, including exclusive distribution agreements for its brands in the UK and Israel.
• Product Performance: JustCBD maintained a gross profit margin of 41%, while Vessel achieved a 39% margin, with both brands adding new wholesale customers.

3. Forward Guidance and Outlook:

• Management expressed optimism about future growth, particularly in Germany and the U.S. markets, as cannabis reform progresses.
• The company anticipates increased sales from medical cannabis in Germany and expects Vessel's growth trajectory to improve significantly in the coming quarters.

4. Bad News, Challenges, or Points of Concern:

• Revenue Decline: The overall revenue decrease reflects the strategic exit from unprofitable segments, which may impact short-term performance.
• Regulatory Challenges: JustCBD faced regulatory issues in Florida that affected sales, although these have been resolved.
• Market Competition: The cannabis market remains competitive, especially with ongoing regulatory changes and the introduction of new products.

5. Notable Q&A Insights:

• Sales Mix Expectations: Management indicated that Germany will continue to contribute approximately 50-55% of sales, with a focus on medical cannabis.
• JustCBD Product Changes: The company is optimistic about profitability improvements in JustCBD following the removal of unprofitable product lines and plans for a significant relaunch.
• Market Trends in Germany: Early signs indicate a doubling of patient sign-ups since the regulatory changes, leading to increased demand and supply shortages.
• Future Market Opportunities: Management highlighted potential growth in the UK and France as future markets to watch for cannabis reform, alongside the ongoing developments in Germany.

Overall, Flora Growth Corp. is navigating a transformative period with strategic initiatives aimed at capitalizing on emerging cannabis markets, while also addressing operational challenges and regulatory hurdles.